Whats new

Whats new.

Maxim - P3 Study for Efti + Keytruda in 1L NSCLC Doses First Patient - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

March 25th 2025

For a copy of this analyst report please contact your Maxim advisor

Go back